Search This Blog

Thursday, July 21, 2016

U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults (NYSE:LLY)

U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.